BlossomHill Therapeutics (BLSM) investor relations material

Executive summary

• Clinical-stage oncology pipeline includes BH-30643 and BH-30236 in early clinical trials and preclinical pan-KRAS candidate BH-501284; no product sales revenue has been generated.

• Q3 2026 net loss was $24.0M; quarter-end cash and cash equivalents were $224.9M following the August IPO.

• FDA aligned on 50 mg twice daily as BH-30643’s recommended Phase 2 dose; pivotal single-arm SOLARA-2 first-patient dosing is expected in Q1 2027.

• BH-501284 preclinical data showed sustained KRAS pathway suppression and durable antitumor activity; BH-30236 translational data are planned for presentation at ASH in December.

Financial highlights

• Q3 R&D expense was $21.9M vs. $14.7M YoY, reflecting BH-30643 clinical development, higher personnel costs and BH-501284 IND-enabling work.

• Q3 G&A expense was $3.6M vs. $2.1M YoY; total operating expenses were $25.5M vs. $16.7M.

• Q3 net loss was $24.0M, or $1.29 per share, vs. $16.0M, or $6.54 per share, YoY; higher operating expenses were partly offset by other income.

• 9M operating expenses were $72.3M vs. $42.3M YoY; net loss was $68.8M vs. $39.7M.

Outlook and guidance

• Cash and cash equivalents of $224.9M are expected to fund planned operations and capital expenditures into Q2 2028; liquidity resources cover at least 12 months after statement issuance.

• BH-30643 milestones: first SOLARA-2 patient in Q1 2027; updated Phase 1 data, including C797S durability, in H1 2027; TKI-naive durability and initial chemotherapy-combination cohort data in H2 2027.

• BH-30236 updated Phase 1 safety and antileukemic data are expected in H1 2027; BH-501284 IND submission is planned for Q1 2027.

• R&D and G&A expenses are expected to rise as programs advance, public-company costs grow and potential commercialization preparation proceeds.